Bhavesh Mohan Lal, MD, UAMS College of Medicine, Little Rock, Arkansas, reviews a study designed to investigate the effects of prior exposure to BCMA-targeting agents on outcomes with…
Praneeth Reddy Sudalagunta, PhD, applied research scientist, Moffitt Cancer Center, Tampa, Florida, discusses the differential effects of bridging therapy on the immune microenvironment as well as outcomes with…
Stacy Loeb, MD discusses how the decision for prostate cancer screening should be an individual one, rather than population-based. Individual risk factors including age, general health, family history,…
It’s highly debated whether patients undergoing radiation therapy for prostate cancer should also have their lymph nodes treated. Janna Andrews, MD, discusses the RTOG trials and their results, which…
With the continual advancement of technology in surgery, one would expect that robotic prostatectomy to be the gold standard of treatment for prostate cancer. However, Judd Moul, MD,…
Journalist David Ewing Duncan, discusses his personal experiences with the technologies of personalized medicine, and touches on the implications of genomics, proteomics, metabolomics and microbiomics. Filmed at FutureMed,…
Judd Moul, MD, explains why he disagrees with the recent move by the US Preventive Services Task Force to give the routine PSA exam a D-rating. He discusses…
Janna Andrews, MD takes us for a tour of the latest technological advancements in the field of radiation therapy delivery for prostate cancer treatment. She explains the benefits…
When should patients seek a biopsy on their prostate? Under what circumstances is a biopsy administered? Stacy Loeb, MD, explains that the American Urological Association’s 2009 guidelines, the PSA,…
Low-risk prostate cancer patients have multiple options when it comes to treatment. Janna Andrews, MD, characterizes the differences between surgical and radiation treatments as well as the various subcategories…
Janna Andrews, MD, discusses the clinical threshold for when a physician should consider preforming a biopsy after preforming a PSA exam to screen for prostate cancer. She also…
How has the nature of chemotherapy and prostate cancer evolved? Janna Andrews, MD, explains that historically, there were not many options for patients who became resistant to androgen deprivation therapy…
